|
|
 |
|
Original Article |
|
|
Neuropsychopharmacology (2002) 27 699-711.10.1038/S0893-133X(02)00346-9
Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder
Frank P Bymaster MS, Jason S Katner BS, David L Nelson Ph.D, Susan K Hemrick-Luecke MS, Penny G Threlkeld MS, John H Heiligenstein MD, S Michelle Morin MS, Donald R Gehlert Ph.D and Kenneth W Perry MS |
|
|
|
Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN USA
Correspondence: Dr Frank P Bymaster, *Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285-0510, USA. Tel.: (317) 276-9444; Fax: (317) 276-5546 E-mail: f.bymaster@lilly.com
|
|
|
|
ABSTRACT
|
|
The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD). We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of atomoxetine with monoamine transporters, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions. Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine (DA) transporters with dissociation constants (Ki) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters. In microdialysis studies, atomoxetine increased extracellular (EX) levels of NE in prefrontal cortex (PFC) 3-fold, but did not alter 5-HTEX levels. Atomoxetine also increased DAEX concentrations in PFC 3-fold, but did not alter DAEX in striatum or nucleus accumbens. In contrast, the psychostimulant methylphenidate, which is used in ADHD therapy, increased NEEX and DAEX equally in PFC, but also increased DAEX in the striatum and nucleus accumbens to the same level. The expression of the neuronal activity marker Fos was increased 3.7-fold in PFC by atomoxetine administration, but was not increased in the striatum or nucleus accumbens, consistent with the regional distribution of increased DAEX. We hypothesize that the atomoxetine-induced increase of catecholamines in PFC, a region involved in attention and memory, mediates the therapeutic effects of atomoxetine in ADHD. In contrast to methylphenidate, atomoxetine did not increase DA in striatum or nucleus accumbens, suggesting it would not have motoric or drug abuse liabilities.
Keywords: Atomoxetine; Methylphenidate; Reboxetine; Attention Deficit/Hyperactivity Disorder; Norepinephrine; Dopamine; Microdialysis; Fos expression |
|
| |
top  |
|
|
|
|
Send to a friend
Download PDF
Full Text
Next Article
Previous Article
Table of Contents